Infectious bronchitis virus (IBV) cross-protection trials were performed in healthy chickens maintained under controlled environmental conditions. Chickens primed or primed and boosted with a Massachusetts (Mass)-type attenuated vaccine were subsequently challenged with either IBV Arkansas (Ark) or GA13-type virulent strains. In addition, Ark-vaccinated chickens were challenged with IBV GA13. Spike protein 1 (S1) amino acid identities between IBV vaccine and challenge strains varied from 76.0% to 77.3%. Contrary to expectations, assessments of clinical signs, viral load, and histopathology indicated a significant level of cross-protection among these antigenically distant IBV strains. Moreover, prime and booster vaccination with Mass protected against GA13 and improved protection against Ark when compared with Mass single vaccination. These results emphasize the need to include both single vaccination control groups and control groups primed and boosted with a single serotype when testing the efficacy of IBV protectotypes and/or novel IBV vaccine combinations against heterologous serotypes under controlled experimental conditions. Such controls are of distinct importance in experiments supporting the introduction of attenuated IBV vaccine strains exotic to regions, since these exotic strains may provide new genetic material for recombination and emergence of novel IBV strains.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1637/11231-070615-Reg.1 | DOI Listing |
Eur Respir Rev
January 2025
Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid Spain
Background: The morbidity and mortality associated with influenza viruses are a significant public health challenge. Annual vaccination against circulating influenza strains reduces hospitalisations and increases survival rates but requires a yearly redesign of vaccines against prevalent subtypes. The complex genetics of influenza viruses with high antigenic drift create an ongoing challenge in vaccine development to address dynamic influenza epidemiology.
View Article and Find Full Text PDFJ Vet Res
December 2024
Department of Omics Analysis, National Veterinary Research Institute, 24-100 Puławy, Poland.
Introduction: In Europe, veterinary vaccines are strictly controlled by the Official Medicines Control Laboratories (OMCLs) of the General European OMCL Network, coordinated by the European Directorate for the Quality of Medicines & HealthCare. Despite a meticulous verification programme for immunological veterinary medicinal products (IVMPs), the products' genomic composition has not yet been subject to evaluation in veterinary pharmacy.
Material And Methods: A study was carried out on Poland's poultry vaccines containing the infectious bronchitis virus which have the greatest market penetration.
mBio
January 2025
Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
Unlabelled: Due to its natural influenza susceptibility, clinical signs, transmission, and similar sialic acid residue distribution, the ferret is the primary animal model for human influenza research. Antibodies generated following infection of ferrets with human influenza viruses are used in surveillance to detect antigenic drift and cross-reactivity with vaccine viruses and circulating strains. Inoculation of ferrets, with over 1,500 human clinical influenza isolates (1998-2019) resulted in lower antibody responses (HI <1:160) to 86% (387 out of 448) influenza B viruses (IBVs) compared to 2.
View Article and Find Full Text PDFmBio
December 2024
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Unlabelled: Respiratory epithelial cells can survive direct infection by influenza viruses, and the long-term consequences of that infection have been characterized in a subset of proximal airway cell types. The impact on the cells that survive viral infection in the distal lung epithelia, however, is much less well-characterized. Utilizing a Cre-expressing influenza B virus (IBV) and a lox-stop-lox tdTomato reporter mouse model, we identified that alveolar type 2 (AT2) pneumocytes, a progenitor cell type in the distal lung, can survive viral infection.
View Article and Find Full Text PDFArch Razi Inst
June 2024
Department of Clinical Science, Faculty of Veterinary Medicine, Karaj Branch, Islamic Azad University, Alborz, Iran.
Infectious bronchitis virus (IBV) has a variety of serotypes that cause many problems in the poultry industry. Two H120 and H120-D274 live vaccines were evaluated against strain IS/1494/06 (variant 2) IBV challenge. The study aimed to determine whether it was possible to achieve success in controlling disease symptoms and pathological lesions and reducing virus shedding by combining two types of vaccines against different severities of poultry IBV.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!